Nexalin Technology is a medical device company that designs and develops neurostimulation products to help combat the ongoing global mental health epidemic. Co. has developed a medical device, referred to as Generation 1, that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Co. has designed and developed new waveform technology to be emitted at 15 milliamps - referred to as Generation 2 which can penetrate deeper into the brain and stimulate associated structures of mental illness. Generation 2 is being tested in pilot trials, for anxiety, insomnia, and depression in the United States. The NXL stock yearly return is shown above.
The yearly return on the NXL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NXL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|